Delivery Order SPE2DB24D2003-SPE2DB25FXMH2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,676.12 to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (30-unit quantity). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 12, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,676.12 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count package), with an ultimate completion date of September 24, 2025. This firm fixed price delivery order, awarded on September 3, 2025, represents a non-competitive set-aside contract and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical...
- The Defense Logistics Agency awarded a $4,049.61 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Ingrezza 60 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed price contract valued at $4,027.70, with an ultimate completion date of August 15, 2025. This non-competitive delivery order was issued on July 25, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The award represents a child order under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $7,352.24 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count) on August 25, 2025, with an ultimate completion date of September 16, 2025. This firm fixed price delivery order represents a non-competitive award and will be fulfilled from the vendor's place of business in Conshohocken, Pennsylvania. The contract is structured as a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (quantity: 30 units) with a ceiling value of $14,704.48. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $4,027.70 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Ingrezza 80 mg capsules (30-count units). This non-set-aside, firm fixed-price contract represents a competitive award to support federal medical procurement needs. The product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 25, 2025. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $7,352.24 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count units). This firm fixed price, non-competitive delivery order was awarded on August 4, 2025, with an ultimate completion date of August 25, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Ingrezza is a specialized neurological medication used in the treatment of tardive dyskinesia,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,027.70 to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units). This is a firm fixed-price, non-competitive delivery order with a completion date of September 11, 2025, and an award date of August 20, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform this work at its corporate office location. Ingrezza is a prescription...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for $8,055.40 on August 21, 2025, for the supply of Ingrezza 80 mg capsules (30-count units). The contract represents a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order falls...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXMH2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ingrezza 40 mg capsules (30-count) with a ceiling value of $3,676.12. This is a firm fixed price delivery order with an ultimate completion date of September 24, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and other government healthcare entities. Ingrezza is a neurological medication used in the treatment of tardive dyskinesia, reflecting the company's portfolio of specialized pharmaceuticals and medical supplies across multiple therapeutic domains. The delivery order is one of numerous competitive awards the vendor has received for pharmaceutical products ranging from generic medications to brand-name specialty drugs, demonstrating the company's established capability to fulfill federal medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 9/3/25 |